Pharmacological agents for nonalcoholic steatohepatitis
- First Online:
- Cite this article as:
- Guillaume, M. & Ratziu, V. Hepatol Int (2013) 7: 833. doi:10.1007/s12072-013-9482-8
The rationale for specific pharmacologic therapy in nonalcoholic steatohepatitis (NASH) is determined by the potential for disease progression and the difficulties, in many patients, to successfully implement diet and lifestyle changes in the long term. Because they correct insulin resistance, insulin-sensitizing agents are attractive candidates for the treatment of NASH. However, two randomized studies have shown that vitamin E, despite having no effect on insulin sensitivity, achieves interesting histological and biochemical efficacy. This review provides an insight into the therapeutic efficacy and safety issues of different pharmacological agents tested in human NASH.